

For further information contact:
Dr Paul D'Sylva
CEO
Commonwealth Biotechnologies, Inc.
858 550 0959 ext. 106

Commonwealth Biotechnologies Announces Appointment of Mark Hober to Vice President, Business Development and Marketing

RICHMOND, VA (Dec 7, 2007) Commonwealth Biotechnologies, Inc. (CBI) (NASDAQ Capital Market: CBTE) is pleased to announce the appointment of Mr. Mark Hober as Vice President, Business Development and Marketing. The articulation of CBI's full-suite of discovery products and services to its target markets and continued growth in these market segments will be his initial goals.

Mr. Hober was previously the Vice President of Business Development for Exelgen, Ltd. (formerly Tripos Discovery Research, Ltd.), a leading provider of drug discovery chemistry services within the CBI group of companies. In that role, he was responsible for directing Exelgen's business development efforts and significantly growing the business establishing multiple drug discovery and synthesis collaborations in North America. Prior to joining Exelgen, Mr. Hober held a variety of positions with increasing responsibility for developing research collaborations and partnerships, implementing strategic marketing plans, and managing sales organizations within the biotechnology industry. Mr. Hober holds a BS in Molecular Biology/Biotechnology and an MBA in Marketing and Finance.

Mr. Hober will be responsible for leading the global business development and marketing organization for CBI with a team of ten sales and marketing professionals located in key territories in Europe, Asia and North America. Paul D'Sylva, CEO of CBI said, "This senior appointment in business development signals CBI's commitment to creating a client-responsive and market led scientific services company. Mark's extensive background in discovery chemistry business development in North America positions CBI well for continued growth across its existing business portfolio and for expansion into complimentary product areas."

Mark Hober stated "There is a strong demand for high quality drug discovery services and the CBI group of companies is well positioned to provide all capabilities from target and hit identification up through pre-clinical studies at this stage. We continue to focus our efforts on ensuring innovative asset development, target area expertise and reliable performance along all aspects of the drug discovery continuum. I look forward to leading our business development and marketing team to ensure CBI's and our partners' success".

About Commonwealth Biotechnologies, Inc.

The CBI group of companies offers cutting-edge research and development products and services to the global life sciences industry. CBI now operates four distinct

business units: (1) CBI Services, a discovery phase contract research organization; (2) Fairfax Identity Laboratories, a DNA reference business; (3) Mimotopes Pty, Ltd, Melbourne, Australia, a peptide and discovery chemistry business; and (4) Exelgen, Ltd, Bude, UK, a medicinal and synthetic discovery chemistry business. Collectively, CBI companies employ over 115 staff in world-class laboratories. For more information, visit CBI on the web at www.cbi-biotech.com.